99 POSTER Models for response to the MEK inhibitor GSK1120212 confirm RAS and BRAF mutations as predictive biomarkers and suggest other, unexpected tumor types for clinical evaluation

Saved in:
Bibliographic Details
Published inEuropean journal of cancer supplements Vol. 6; no. 12; pp. 33 - 34
Main Authors Wooster, R, Cornwell, W, Jing, J, Greshock, J, Gilmartin, A, Sutton, D, Jackson, J, Laquerre, S, Weber, B, Degenhardt, Y
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 2008
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text

Cover

More Information
ISSN:1359-6349
1878-1217
DOI:10.1016/S1359-6349(08)72031-7